Amikacin

Aminoglycoside Antibacterial — DERMATOLOGICALS

Key facts

Amikacin is an ofp drug in the Aminoglycoside Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1981. DrugCentral lists 1 molecular target, including mphB. Recorded indications include Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia, Bacterial meningitis and Bacterial meningitis due to Gram-negative bacteria.

• Approval status: ofp (first approved 1981 by the FDA).
• Drug class: Aminoglycoside Antibacterial.
• Molecular targets: mphB (1 listed in DrugCentral).
• Indications: Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia, Bacterial meningitis, Bacterial meningitis due to Gram-negative bacteria and Bacterial pneumonia and others.
• ATC code: D06AX12 (Other antibiotics for topical use).
• Molecular formula: C22H43N5O13; molecular weight 585.61 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (61)

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial infection due to Serratia
• Bacterial meningitis
• Bacterial meningitis due to Gram-negative bacteria
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Burn Wound Infections
• Cholangitis
• Complicated Bacterial Peritonitis
• Complicated Proteus UTI
• Complicated Urinary Tract Infection due to Acinetobacter
• Complicated Urinary Tract Infections
• Complicated UTI with Pseudomonas Aeruginosa
• Diverticulitis of gastrointestinal tract
• Enterobacter Meningitis
• Enterobacter Pneumonia
• Escherichia coli meningitis
• Escherichia coli urinary tract infection
• Gram-Negative Aerobic Bacillary Pneumonia
• Infection due to Enterobacteriaceae
• Infection due to Escherichia coli
• Infection due to Pseudomonas aeruginosa
• Infection of bone
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• Infectious disorder of joint
• Klebsiella Septicemia
• Meningitis due to Klebsiella mobilis
• Neonatal meningitis
• + 31 more

Off-label uses (22)

• Acute tuberculosis
• Citrobacter Complicated UTI
• Citrobacter Meningitis
• Citrobacter Osteomyelitis
• Citrobacter Pneumonia
• Citrobacter Septicemia
• Enteric campylobacteriosis
• Infection by Yersinia enterocolitica
• Listeria Monocytogenes Septicemia
• Necrotizing enterocolitis in fetus OR newborn
• Pseudotuberculosis
• Pulmonary tuberculosis
• Pyrexia of unknown origin
• Skin and Skin Structure Acinetobacter Infection
• Skin and Skin Structure Citrobacter Infection
• Synergy for Bacterial Meningitis
• Synergy for Group B Streptococcal Septicemia
• Synergy for Neonatal Meningitis
• Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
• Synergy for P. Aeruginosa Infection in Cystic Fibrosis
• Synergy for Staphylococcal Endocarditis
• Synergy for Staphylococcal Infections

Contraindications (11)

• Amikacin Toxicity
• Dehydration
• Disorder of the 8th Cranial Nerve
• Hypocalcemia
• Infant Botulism
• Kidney disease
• Myasthenia gravis
• Parkinsonism
• Pregnancy, function
• Tinnitus
• Vertigo

Mechanism & targets

• Established pharmacologic class: Aminoglycoside Antibacterial

Molecular targets (1)

Target	Gene	Action	Activity
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)	mphB	unknown	Km 4.20

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-03-23	PMDA	—	Insmed GK
1981-01-22	FDA	—	APOTHECON

ATC classification

ATC code	Therapeutic hierarchy
D06AX12	DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › ANTIBIOTICS FOR TOPICAL USE › Other antibiotics for topical use
J01GB06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › AMINOGLYCOSIDE ANTIBACTERIALS › Other aminoglycosides
J01RA06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
S01AA21	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antibiotics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: MT-RNR1 · Actionable PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	1296.1
Ototoxicity	697.4
Pathogen resistance	654.9
Drug reaction with eosinophilia and systemic symptoms	489.1
Deafness	481.0
Septic shock	456.8
Therapy interrupted	320.9
Drug ineffective	320.2
Multiple organ dysfunction syndrome	309.5
Thrombocytopenia	296.4
Dysphonia	295.5
Mycobacterium abscessus infection	277.9

Chemical structure

• Molecular formula: C₂₂H₄₃N₅O₁₃
• Molecular weight: 585.61 g/mol
• CAS number: 37517-28-5
• InChIKey: LKCWBDHBTVXHDL-RMDFUYIESA-N
• PubChem CID: 37768

NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Amikacin used for?

DrugCentral lists the following indications for Amikacin: Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia, Bacterial meningitis, Bacterial meningitis due to Gram-negative bacteria, Bacterial pneumonia, Bacterial septicemia, Bacterial urinary infection and Burn Wound Infections and others.

How does Amikacin work?

Its molecular targets in DrugCentral include mphB.

When was Amikacin first approved?

Amikacin was first approved by the FDA in 1981.

What drug class does Amikacin belong to?

Amikacin is in the Aminoglycoside Antibacterial class.

What is the chemical formula of Amikacin?

Amikacin has the molecular formula C22H43N5O13 and a molecular weight of 585.61 g/mol.

Sources

• DrugCentral drug card 157 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL177 — compound record and bioactivity
• PubChem CID 37768 — chemical identifiers
• DrugBank DB00479 — drug record
• FDA UNII 84319SGC3C — substance identity
• DailyMed: FDA labels for Amikacin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.